Search
Repligen Corp
RGENAdd to Watchlist
136.130USD
-0.870-0.63%
Market hours （ET）Quotes delayed by 15 min
7.67BMarket Cap
149.03P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-0.63%
5 Days
+7.55%
1 Month
+9.83%
6 Months
-17.86%
Year to Date
-16.92%
1 Year
+10.17%
Key Figures
137.770Open
138.850High
273.47KVolume
149.03P/E TTM
52.14P/E Dynamic
--Dividend TTM
0.49%Turnover Ratio
137.000Prev. Close
134.010Low
28.82MTurnover
LossP/E Static
3.64P/B
0.00%Div Yield TTM
1.78%ROA
175.77052wk High
0.47Volume Ratio
-25.51MNet Profit
56.33MShares
0.9135EPS TTM
1.09Beta
2.51%ROE
100.99052wk Low
3.53%Amplitude
55.74%Gross Margin
7.67BMarket Cap
3.82Reward/Risk
2.75%Risk Rate
TradingKey Stock Score of Repligen Corp
Currency: USD Updated: 2026-06-29Key Insights
Repligen Corp's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 28 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 177.75.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Repligen Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Repligen Corp Highlights
StrengthsRisks
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 16.75% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 738.26M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 149.98, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 65.93M shares, decreasing 3.85% quarter-over-quarter.
Held by Lee Ainslie
Star Investor Lee Ainslie holds 1.58M shares of this stock.
Analyst Rating
Based on
22
analysts
Buy
Current Rating
177.749
Target Price
+20.91%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Repligen Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Repligen Corp Info
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
Ticker SymbolRGEN
CompanyRepligen Corp
CEOLoeillot (Olivier)
Websitehttps://www.repligen.com/
Related Instruments
-0.77%
-1.07%
-1.11%
-1.02%
-1.28%
-0.12%
-4.84%
-2.02%
-1.18%
-0.15%
-0.61%
-2.39%
-0.06%
-0.82%
+1.48%
-2.47%
-2.35%
-0.24%
-1.65%
-0.12%Popular Instruments
52356.700
+203.500 (+0.39%)
30203.500
+495.800 (+1.67%)
7490.100
+57.900 (+0.78%)
15601.000
+150.000 (+0.97%)
71089.000
+615.000 (+0.87%)
6325.800
+70.000 (+1.12%)
69.861
-0.455 (-0.65%)
288.800
+7.060 (+2.51%)
198.350
+3.380 (+1.73%)
4027.370
+11.780 (+0.29%)
FAQs
What is the current price of Repligen Corp (RGEN)?
The current price of Repligen Corp (RGEN) is 137.00.
What is the symbol of Repligen Corp?
The ticker symbol of Repligen Corp is RGEN.
What is the 52-week high of Repligen Corp?
The 52-week high of Repligen Corp is 175.77.
What is the 52-week low of Repligen Corp?
The 52-week low of Repligen Corp is 100.99.
What is the market capitalization of Repligen Corp?
The market capitalization of Repligen Corp is 7.73B.
Is Repligen Corp (RGEN) currently rated as Buy, Hold, or Sell?
According to analysts, Repligen Corp (RGEN) has an overall rating of Buy, with a price target of 177.75.
What is the Earnings Per Share (EPS TTM) of Repligen Corp (RGEN)?
The Earnings Per Share (EPS TTM) of Repligen Corp (RGEN) is 0.87.
